§ 520.1265 Lincomycin and spectinomycin powder.

(a) Specifications. The following salts of lincomycin and spectinomycin are present in a soluble powder in the ratio of 1 to 2 on the basis of equivalency of lincomycin base to equivalency of spectinomycin base:

1. Lincomycin hydrochloride monohydrate and spectinomycin sulfate tetrahydrate.
2. Lincomycin hydrochloride monohydrate and spectinomycin dihydrochloride pentahydrate.

(b) Sponsors. See sponsors in §510.600(c) of this chapter for use as in paragraph (d) of this section.

1. No. 000009 for use of product described in paragraph (a)(1) of this section.
2. Nos. 057561, 061623, and 066104 for use of product described in paragraph (a)(2) of this section.

(c) Tolerances. See §§556.360 and 556.600 of this chapter.

(d) Conditions of use. See §§556.360 and 556.600 of this chapter.

(1) Dogs—(A) Amount. 2 grams of antibiotic activity per gallon of drinking water; administer as the sole source of water for the first 5 to 7 days of life.

(B) Indications for use. As an aid in the control of air sacculitis caused by either Mycoplasma synoviae or M. gallisepticum susceptible to lincomycin-spectinomycin and complicated chronic respiratory disease (air sac infection) caused by Escherichia coli and M. gallisepticum susceptible to lincomycin-spectinomycin.

§ 520.1284 Sodium liothyronine tablets.

(a) Specifications. Sodium liothyronine tablets consist of tablets intended for oral administration which contain liothyronine at 60 or 120 micrograms per tablet, as the sodium salt.

(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(c) Conditions of use. (1) It is indicated in cases of hypothyroidism in dogs.

(2) It is administered orally to dogs at levels up to 12.8 micrograms per kilogram of body weight per day. Dosage should be adjusted according to the severity of the condition and the response of the patient. Dosage at the total replacement level (12.8 μg per kilogram of body weight) should be considered for initiating therapy and then titrated downward for optimum maintenance effect. Twice daily administration is recommended.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1288 Lufenuron tablets.

(a) Specifications—(1) Tablets containing 45, 90, 204.9, or 409.8 milligrams (mg) lufenuron for use as in paragraphs (c)(1)(i), (c)(1)(ii)(A), (c)(1)(iii), (c)(2)(i), (c)(2)(ii)(A), and (c)(2)(ii)(B) of this section.

(2) Flavored tablets containing 45, 90, 204.9, or 409.8 milligrams (mg) lufenuron for use as in paragraphs (c)(1)(i), (c)(1)(ii)(A), or (c)(1)(ii)(B), and (c)(2)(ii)(A), and (c)(2)(ii)(B) of this section.

(3) Flavored tablets containing 90 or 204.9 mg lufenuron for use as in paragraphs (c)(2)(i), (c)(2)(ii)(A), or (c)(2)(ii)(B), and (c)(2)(ii)(A), and (c)(2)(ii)(B) of this section.

(4) Flavored tablets containing 135 or 270 mg lufenuron for use as in paragraphs (c)(2)(i), (c)(2)(ii)(A), or (c)(2)(ii)(B), and (c)(2)(ii)(A), and (c)(2)(ii)(B) of this section.

(b) Sponsor. See No. 058198 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. Minimum of 10 mg lufenuron per kilogram (4.5 mg per pound (lb)) of body weight, once a month.

(ii) Indications for use—(A) For the prevention and control of flea populations.
§ 520.1289 Lufenuron suspension.

(a) Specifications. Each individual dose pack contains either 135 or 270 milligrams of lufenuron.

(b) Sponsor. See No. 058198 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Minimum of 30 mg lufenuron per kilogram (13.6 mg/lb) of body weight, once a month.

(d) Indications for use—(A) For the control of flea populations.

(B) The concurrent use of flavored lufenuron tablets described in paragraph (a)(2) of this section as in paragraph (c)(1)(ii)(A) of this section with nitenypram tablets as in §520.1510(d)(1) of this chapter is indicated to kill adult fleas and prevent flea eggs from hatching.

(iii) Limitations. For use in dogs and puppies 4 weeks of age and older.

(2) Cats—(1) Amount. Minimum of 30 mg lufenuron per kilogram (13.6 mg/lb) of body weight, once a month.

(ii) Indications for use—(A) For the control of flea populations.

(B) The concurrent use of flavored lufenuron tablets described in paragraph (a)(3) of this section as in paragraph (c)(2)(ii)(A) of this section with nitenypram tablets as in §520.1510(d)(2) of this chapter is indicated to kill adult fleas and prevent flea eggs from hatching.

(iii) Limitations. For use in cats and kittens 4 weeks of age and older.

[68 FR 51905, Aug. 29, 2003]

§ 520.1310 Marbofloxacin tablets.

(a) Specifications. Each tablet contains 25, 50, 100, or 200 milligrams (mg) marbofloxacin.

(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Amount. 1.25 mg per pound (/lb) of body weight once daily, but may be increased to 2.5 mg/lb of body weight once daily.

(2) Indications for use. For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this drug in food-producing animals.


§ 520.1315 Maropitant.

(a) Specifications. Each tablet contains 16, 24, 60, or 160 milligrams (mg) maropitant as maropitant citrate.

(b) Sponsor. See No. 000069 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Indications for use and amount. For the prevention of acute vomiting, administer a minimum of 2.0 mg per kilogram (/kg) body weight once daily for up to 5 consecutive days. For the prevention of vomiting due to motion sickness, administer a minimum of 8.0 mg/kg body weight once daily for up to 2 consecutive days.

(2) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[72 FR 9243, Mar. 1, 2007]

§ 520.1320 Mebendazole oral.

(a) Chemical name. Methyl 5-benzoylbenzimidazole-2-carbamate.

(b) Specifications. As oral powder: Each gram contains either 40 or 166.7 milligrams of mebendazole. As oral paste: Each gram contains 200 milligrams of mebendazole. As oral suspension: Each milliliter contains 33.3 milligrams of mebendazole.

(c) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(d) Conditions of use—(1) Horses—(1) Amount. 1 gram of mebendazole per 250